Nervous System Diseases

Heart and Blood Diseases

Symptoms and General Pathology

Wounds and Injuries

All Conditions

Infections

Neoplasms

Hematoma, Subdural

Virus Diseases

Papilloma

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

All Drugs and Chemicals

Vaccines

Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017

Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.

A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.

Rosa Gonzalez-Guarda, PhD

The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adolescents and reduce barriers to receiving the second shot of the vaccine series.

SDH of HPV Vaccine Completion

Social Determinants of HPV Vaccine Completion Among Adolescents

Adolescents who completed the required HPV vaccine doses (e.g. two or three doses based on the CDC's vaccine administration guidelines for adolescents' ages 11 to 14 years) during the January 2017 to February 2019 observation period.

Adolescents who received the required number of doses for vaccine completion, defined as the receipt of two or three doses based on the CDC's guidelines for adolescents' ages 11 to 14 years, within 14-months from their first vaccine dose.

Duke University

Participants in the Cohort of Adolescents From EHR group were not monitored/assessed for adverse events.

Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017. Adolescents were stratified into two groups: Completer (defined as adolescents who received two vaccine doses within a 14-month period) and Non-Completer (defined as adolescents who did not receive two vaccine doses).

Adolescents Ages 11 to 14 Years

Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent. Parents were stratified into two groups (Completer or Non-Completer as described in the adolescent group) based on the adolescent's vaccination status.

Parent of Adolescents

Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017. Adolescents were stratified into two groups: Completer (defined as adolescents who received two vaccine doses within a 14-month period) and Non-Completer (defined as adolescents who did not receive two vaccine doses). Qualitative sample.

Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent. Parents were stratified into two groups (Completer or Non-Completer as described in the adolescent group) based on the adolescent's vaccination status. Qualitative sample.

A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period. Quantitative sample.

Cohort of Adolescents From Electronic Health Record (EHR)

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

American Indian or Alaska Native

Asian

Native Hawaiian or Other Pacific Islander

Non Hispanic Black or African American

Non-Hispanic White

More than one race

Hispanic Other

Hispanic White

Non-Hispanic Other

Unknown or Not Reported

The sample size of the cohort of adolescent group for the race variable differs from overall quantitative sample population (N=3044) because race information was not provided for some participants who reported Hispanic ethnicity.

Race/Ethnicity, Customized

United States

Region of Enrollment

Completer defined as receiving 2 or 3 vaccine doses within 14-month period determined by the CDC's vaccine administration schedule. Non-completer defined as receiving only 1 vaccine dose within 14-month period.

HPV vaccine completion status

There is no quantitative results beyond demographics for the Adolescents ages 11 to 14 years and parent of adolescents groups as this was not part of the aim of the study.

Dr. Lisa Mansfield

Vaccine completion rates were only analyzed for the quantitative sample of adolescents using the EHR data (N=3044).

Overall HPV Vaccine Completion Rates

Cohort of Adolescents From EHR

HPV Vaccine Completion Within 14-Months

Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017. Adolescents were stratified into two groups: Completer (defined as adolescents who received two vaccine doses within a 14-month period) and Non-Completer (defined as adolescents who received only one vaccine dose within 14-month period). Qualitative sample.

Spots Global Cancer Trial Database for SDH of HPV Vaccine Completion

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial